Welcome to our dedicated page for Orthofix Med news (Ticker: OFIX), a resource for investors and traders seeking the latest updates and insights on Orthofix Med stock.
Orthofix Medical Inc. (NASDAQ: OFIX) is a global medical technology company headquartered in Lewisville, Texas, with a focus on musculoskeletal care. The Orthofix news stream highlights developments across its spinal hardware, bone growth therapies, specialized orthopedic solutions, biologics and enabling technologies, including updates related to the 7D FLASH™ Navigation System.
Investors and healthcare professionals following Orthofix news can review regular earnings announcements, where the company reports net sales and segment performance for Bone Growth Therapies, Spinal Implants, Biologics and Enabling Technologies, Global Spine and Global Orthopedics. These releases often include commentary on trends in U.S. Spine Fixation, bone growth therapy performance, and the progress of its orthopedics business focused on limb reconstruction.
News coverage also features regulatory and product milestones, such as FDA 510(k) clearance and CE Mark for the TrueLok™ Elevate Transverse Bone Transport System and the global commercial launch of TrueLok Elevate. Orthofix uses these announcements to describe how TrueLok Elevate fits into its TrueLok family of multiplanar external fixators and supports limb preservation and diabetic wound-related treatment needs.
In addition, Orthofix issues releases about upcoming investor conference appearances and the timing of quarterly financial results and conference calls. For anyone tracking OFIX, this news page provides a centralized view of the company’s public communications on financial performance, product launches, regulatory clearances and investor events.
Orthofix Medical has appointed Max Reinhardt as President of its Global Spine business, effective June 10, 2024. Reinhardt, with over 30 years of experience in MedTech and pharmaceuticals, will be a part of the Executive Leadership Team, leading SeaSpine. He has held significant positions at Johnson & Johnson, including Worldwide President of DePuy Synthes Spine, where he achieved the number two market share position in the spine market. Orthofix CEO Massimo Calafiore praised Reinhardt's robust leadership and strategy execution skills. Reinhardt's prior roles also include senior positions at Steris, Olympus, and Pacira Biosciences.
Orthofix, a global leader in spine and orthopedics, has won the 'Best Patient Experience Solution' award at the 2024 MedTech Breakthrough Awards for its STIM onTrack™ mobile app. The app, compatible with FDA-approved bone growth therapy devices like CervicalStim™, SpinalStim™, and PhysioStim™, tracks patient compliance data and aids in recovery by providing daily treatment reminders, usage calendars, and patient-reported outcome measures. The app enhances patient engagement by allowing remote monitoring and direct communication with physicians. This is Orthofix's second consecutive win at the MedTech Breakthrough Awards.
Orthofix Medical Inc. (NASDAQ:OFIX) has received FDA 510(k) clearance to market its innovative Rodeo Telescopic Nail designed to treat deformities or fractures in patients with osteogenesis imperfecta. The device stabilizes limbs and accommodates natural growth in pediatric patients, addressing biomechanical challenges in a streamlined procedure. The system enhances bone fixation in fragile OI patients, optimizes operational efficiency, reduces costs, and lessens contamination risks. This marks Orthofix's dedication to serving the pediatric market with tailored solutions for conditions like OI.
Orthofix Medical Inc. (NASDAQ:OFIX) reported strong first quarter 2024 results with net sales of $188.6 million, a 7.7% increase on a reported basis. The company saw growth across key segments, including Bone Growth Therapies, U.S. Spine Fixation, and Global Orthopedics. Despite a net loss of $36 million, the Non-GAAP Adjusted EBITDA increased to $7.7 million, showing a 220 basis point expansion. Orthofix raised its full-year net sales guidance to $790.0-$795.0 million, emphasizing continued growth and profitability.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Orthofix Med (OFIX)?
What is the market cap of Orthofix Med (OFIX)?
